With Incivek Deflated, Vertex’s HCV Roller Coaster Ride Hinges On Phase II Candidate VX-135

Along with steep job cuts in the commercial force behind hepatitis C drug Incivek, Vertex is nearing a go/no-go decision on development of Phase II nucleoside polymerase inhibitor VX-135 for HCV. Incivek earned nearly $1 billion in its first 10 months of sales, but fell to $86 million in the third quarter of 2013.